Teva slides 5% as bearish options flow spikes, with traders weighing deal-related and regulatory crosscurrents

Teva Pharmaceutical Industries Ltd. (TEVA) is down 5.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a burst of bearish options positioning (heavy put activity), which can amplify downside when the stock is already prone to volatility. Investors may also be reassessing the near-term financial impact of Teva’s recently announced $700 million acquisition agreement, while routine regulatory housekeeping added background noise.

Details:

Unusual put-option activity signaled increased downside hedging/speculation, which can pressure shares as market makers adjust hedges.

Teva recently signed an agreement to buy Emalex Biosciences, featuring a large upfront cash payment plus potential additional milestone payments and royalties, with closing targeted for the third quarter of 2026.

A federal notice disclosed the withdrawal of approvals for certain abbreviated generic-drug applications tied to Teva and affiliates (effective June 8, 2026) after the applicants said the products were no longer marketed.

This could also be simple profit-taking after prior strength, as no single company-specific negative headline was clearly dominant during the session.

Sources:

TipRanks, U.S. SEC, U.S. Federal Register

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TEVA Insider Trading Activity

$TEVA insiders have traded $TEVA stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.

Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:

RICHARD D FRANCIS (President and CEO) has made 0 purchases and 4 sales selling 486,353 shares for an estimated $15,726,934.
ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) sold 345,810 shares for an estimated $11,634,708
RICHARD DANIELL (EVP, Europe Commercial) has made 0 purchases and 7 sales selling 353,093 shares for an estimated $11,016,289.
MARK SABAG (See "Remarks") has made 0 purchases and 3 sales selling 278,994 shares for an estimated $8,102,570.
ERIC A HUGHES (See "Remarks") has made 0 purchases and 4 sales selling 101,572 shares for an estimated $3,281,447.
ROBERTO MIGNONE sold 77,400 shares for an estimated $2,340,645
EVAN LIPPMAN (EVP, Business Development) has made 0 purchases and 2 sales selling 41,658 shares for an estimated $1,482,366.
MATTHEW SHIELDS (EVP, Global Operations) sold 17,295 shares for an estimated $547,704
CHRISTINE FOX (EVP, U.S. Commercial) has made 0 purchases and 2 sales selling 17,022 shares for an estimated $546,302.
PLACID JOVER (See "Remarks") sold 14,150 shares for an estimated $448,107
AMIR WEISS (Chief Accounting Officer) sold 12,300 shares for an estimated $371,504
BRIAN SAVAGE (Interim Chief Legal Officer) has made 0 purchases and 2 sales selling 2,401 shares for an estimated $76,916.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive TEVA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$TEVA Hedge Fund Activity

We have seen 321 institutional investors add shares of $TEVA stock to their portfolio, and 292 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

NORGES BANK added 33,318,265 shares (+1786.8%) to their portfolio in Q4 2025, for an estimated $1,039,863,050
WCM INVESTMENT MANAGEMENT, LLC added 26,813,522 shares (+191.4%) to their portfolio in Q1 2026, for an estimated $807,623,282
GLENVIEW CAPITAL MANAGEMENT, LLC removed 10,032,460 shares (-60.1%) from their portfolio in Q1 2026, for an estimated $302,177,695
SLATE PATH CAPITAL LP removed 7,927,998 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $247,432,817
BLACKROCK, INC. added 6,833,776 shares (+11.7%) to their portfolio in Q1 2026, for an estimated $205,833,333
CAPITAL WORLD INVESTORS added 6,472,554 shares (+274.1%) to their portfolio in Q1 2026, for an estimated $194,953,326
RUBRIC CAPITAL MANAGEMENT LP removed 6,105,510 shares (-28.6%) from their portfolio in Q1 2026, for an estimated $183,897,961

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TEVA Analyst Ratings

Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Truist Securities issued a "Buy" rating on 04/30/2026
Barclays issued a "Overweight" rating on 01/30/2026
Jefferies issued a "Buy" rating on 01/06/2026
Piper Sandler issued a "Overweight" rating on 12/22/2025
Goldman Sachs issued a "Buy" rating on 12/19/2025
JP Morgan issued a "Overweight" rating on 12/16/2025

To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative's $TEVA forecast page.

$TEVA Price Targets

Multiple analysts have issued price targets for $TEVA recently. We have seen 9 analysts offer price targets for $TEVA in the last 6 months, with a median target of $42.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $40.0 on 05/06/2026
David Amsellem from Piper Sandler set a target price of $42.0 on 04/30/2026
Ashwani Verma from UBS set a target price of $42.0 on 04/30/2026
Chris Schott from JP Morgan set a target price of $40.0 on 04/30/2026
Les Sulewski from Truist Securities set a target price of $45.0 on 04/30/2026
Jason Gerberry from B of A Securities set a target price of $42.0 on 04/09/2026
Matt Dellatorre from Goldman Sachs set a target price of $45.0 on 02/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.